Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04640142 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Deficiency

Interventions

BIOLOGICAL: Newnorm

Sponsor

Octapharma